Abstracts tagged "glucocorticoids"

Abstract Number: 0831 • ACR Convergence 2022
Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
Kinza Muzaffar¹, Sulman Hasan², Sarwat umer², Mohammad Alfrad Nobel Bhuiyan², Kavya Vadlamudi², Manush Sondhi², Anusheh Ali¹, Tabitha Muutu² and Samina Hayat¹, ¹Louisiana State University, Shreveport, LA, ²LSU Health Shreveport, Shreveport, LA
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease which can affect the GI system in about 5-10% of cases, out of which 11-80% can have hepatic…
Abstract Number: 1620 • ACR Convergence 2022
Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study
Alwin Sebastian¹, alessandro tomelleri², PIERLUIGI MACCHIONI³, Giulia Klinowski³, Carlo Salvarani⁴, Abdul Kayani⁵, Mohammad Tariq⁵, Diana Prieto-Peña⁶, Edoardo Conticini⁷, Muhammad Khurshid⁸, Sue Inness⁹, Jo Jackson⁹, Kornelis van der Geest¹⁰ and Bhaskar Dasgupta⁵, ¹University Hospital Limerick, Dooradoyle, Ireland, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ³IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁴Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁵Mid and South Essex University Hospital Groups, Southend, United Kingdom, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁸University Hospital Dorset, NHS foundation trust, UK, Poole, United Kingdom, ⁹University of Essex, School of Sport, Rehabilitation and Exercise science, Colchester, United Kingdom, ¹⁰University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: The presentation of new-onset giant cell arteritis (GCA) is highly variable. It is vital to make a secure diagnosis to minimise the risk for…
Abstract Number: 0767 • ACR Convergence 2021
Medication Use in Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
Jordan Roberts¹, Laura Berbert¹ and Mary Beth Son², ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA
Background/Purpose: Black and Hispanic children with pediatric lupus (pSLE) have higher morbidity and mortality, but the extent to which differences in outcomes may be related…
Abstract Number: 1859 • ACR Convergence 2021
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
Adam Geressu¹ and Marwan Bukhari², ¹Royal Lancaster Infirmary, Lancaster, United Kingdom, ²British Society for Rheumatology, London, United Kingdom
Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…
Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Brian Coburn¹, Michael George¹, Joshua Baker¹, Jesse Hsu², Qufei Wu¹, Lang Chen³, Fenglong Xie³, Huifeng Yun⁴ and Jeffrey Curtis⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…
Abstract Number: 0856 • ACR Convergence 2021
Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus
Alexander Hall¹, Michael Trevisonno¹, Elizabeth Murray¹, Omoakhe Tisor¹, Emily Stanford¹, Jacob Gaines¹, Noor Anvery¹ and Ellen Ginzler², ¹SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: The risk of COVID-19 infection among patients with Systemic Lupus Erythematosus (SLE) is poorly understood. Patients with SLE often take medications which modulate the…
Abstract Number: 1140 • ACR Convergence 2021
Fracture Risk in DXA-Appropriate Patients on Glucocorticoids: Is Everyone Tested According to Screening Guidelines?
Alexandra Chop¹, Rajesh Kupuraju¹, Ruchi Patel¹, Kristen Salava¹, Madhuri Duggirala¹, Aparna Baburaj¹, Andrea Berger², Jason Brown¹ and David Bulbin³, ¹Geisinger Medical Center, Danville, PA, ²Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: Glucocorticoids are commonly prescribed for a multitude of indications, yet have many side effects, one of which is glucocorticoid induced osteoporosis (GIOP). The 2017…
Abstract Number: 1144 • ACR Convergence 2021
Underestimation of the Fracture Risk by the FRAX Formula in Chronic Glucocorticoid Users: A 10-year Longitudinal Validation Study
Chi Chiu Mok¹, Ling Yin Ho², Sau Mei TSE² and Kar Li Chan³, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong
Background/Purpose: To compare the actual fracture incidence over 10 years in a longitudinal cohort of patients using glucocorticoids (GCs) with the risk prediction from FRAX…
Abstract Number: 1149 • ACR Convergence 2021
Efficacy of Alendronate for Prevention of New Fractures and Vertebral Deformities in Patients with Rheumatologic Disorders on Chronic Glucocorticoid Therapy: A Systematic Review and Meta-analysis
Saffa Iftikhar¹, Waleed Khokher², Ashu Acharya¹, Joan Gekonde³, Nithin Kesireddy², Rawish Fatima¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH, ³University of Toledo, Sylvania Township, OH
Background/Purpose: Glucocorticoids are commonly used in patients with rheumatologic conditions including but not limited to Rheumatoid Arthritis, Polymyalgia Rheumatica, Systemic Lupus Erythematous and so on.…
Abstract Number: 1264 • ACR Convergence 2021
Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated…
Abstract Number: 1283 • ACR Convergence 2021
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
Karen Costenbader¹, Yoshiyuki Abe², Laurent Arnaud³, George Bertsias⁴, Norma Lynn Fox⁵, Mathew Gibb⁶, Anne Hammer⁵, Alexa Meara⁷, Holly Quasny⁸, David Roth⁵ and Tania Gonzalez-Rivera⁵, ¹Brigham and Women's Hospital, Belmont, MA, ²Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ⁴Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece, ⁵GlaxoSmithKline, Collegeville, PA, ⁶Veramed Ltd., Twickenham, United Kingdom, ⁷Ohio State University Wexner Medical Center, Columbus, OH, ⁸GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Glucocorticoids (GC) play an important role in rapid systemic lupus erythematosus (SLE) symptom relief. However, chronic GC use increases organ damage risk; and treatment…
Abstract Number: 1398 • ACR Convergence 2021
Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis
Alojzija Hocevar¹, Rok Jese¹, Jelka Kramaric², Matija Tomšič³ and Ziga Rotar³, ¹UKC Ljubjana, Ljubjana, Slovenia, ²UKC Ljubjana, Ljubjana, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Adrenal insufficiency is frequently neglected and underappreciated complication of systemic glucocorticoid therapy. We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in…
Abstract Number: 1408 • ACR Convergence 2021
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Jesús T. Sánchez-Costa¹, Iñigo Hernández-Rodríguez², Elisa Fernández-Fernández³, María T. Silva-Diaz⁴, Jesús A. Valero-Jaimes⁵, Ismael González-Fernández⁶, Julio Sánchez⁷, Judit Lluch⁸, Eva Galindez-Agirregoikoa⁹, Javier Mendizábal-Mateos¹⁰, Pia M. Lois Bermejo¹¹, Javier Loricera¹², Alejandro Muñoz¹³, Cristina Valero-Martínez¹⁴, Patricia Moya¹⁵, Carmen Larena-Grijalba¹⁶, Vanessa A. Navarro-Angeles¹⁷, Joan Calvet-Fontova¹⁸, Ivette Casafont¹⁹, Francisco Ortiz-Sanjuán²⁰, Selene Labrada-Arrabal²¹, Jaime Calvo-Alén²², Carlota L. Iñiguez-Ubiaga²³, Vanesa Hernández²⁴, Cristina Campos-Fernández²⁵, María Alcalde-Villar²⁶, Antonio Juan-Mas²⁷, Eugenio De Miguel²⁸, Javier Narvaez²⁹, Miguel Ángel gonzalez-Gay³⁰, Noemí Garrido-Puñal³¹, Paula V. Estrada-Alarcon¹⁷ and Ricardo Blanco³², ¹Spanish Society of Rheumatology, Madrid, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ³Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁴Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ⁵Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ⁶Hospital Universitario de León, León, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ⁹Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰H. Navarra, Navarra, Spain, ¹¹Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevial, Spain, ¹⁴Hospital Universitario de La Princesa, Madrid, Spain, ¹⁵Hospital Sant Pau, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁷Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitari Parc Tauli, Sabadell, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, ²⁰H. La Fe, Valencia, Spain, ²¹Hospital del Mar, Barcelona, Spain, ²²Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁶Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁷Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁸Hospital Universitario La Paz, Madrid, Spain, ²⁹Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁰Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³¹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Glucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment,…
Abstract Number: 1416 • ACR Convergence 2021
Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis
Idil Esen¹, Philip Therkildsen², Berit Dalsgaard Nielsen², Anna van 't Ende¹, Annemieke Boots¹, Peter Heeringa¹, Ellen-Margrethe Hauge², Elisabeth Brouwer¹ and Yannick van Sleen³, ¹University Medical Center Groningen, Groningen, Netherlands, ²Aarhus University Hospital, Aarhus, Denmark, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is the large and medium vasculitis that affects elderly people GCA frequently overlaps with polymyalgia rheumatica (PMR). PMR is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].